Regulatory T Cell Therapy Patents

Regulatory T cell (Treg) therapy patents cover CAR-Treg innovations; TCR-Treg/antigen-specificity innovations; Treg-stability (FoxP3) innovations; and expansion, induced-Treg, and manufacturing innovations — with IP held by Treg-therapy companies (in a field using immune-SUPPRESSIVE cells to restore tolerance and treat autoimmune/inflammatory disease — the inverse of cancer immunotherapy). WHY REGULATORY T CELL THERAPY: REGULATORY T cells (Tregs) are the immune system's 'brakes' — they SUPPRESS immune responses and maintain TOLERANCE; in autoimmune disease, transplant rejection, and chronic inflammation, tolerance is broken, so giving/engineering Tregs can RESTORE it (treating the disease at its root, locally and durably, rather than broadly immunosuppressing the patient with drugs); this is the OPPOSITE goal of CAR-T/cancer immunotherapy (which boosts immunity to kill). MAJOR Treg-THERAPY PATENT HOLDERS: SONOMA BIOTHERAPEUTICS (engineered/CAR-Tregs for autoimmune), QUELL THERAPEUTICS (CAR-Tregs for transplant/autoimmune), ABATA THERAPEUTICS (TCR-Tregs — antigen-specific, e.g., MS), GENTIBIO (engineered iTregs from conventional T cells), COYA, Tr1X (Tr1 cells). CAR-Tregs, TCR-Tregs/antigen-specificity, Treg stability, and expansion/induced-Tregs/manufacturing are the core Treg-therapy patent domains — and CAR/TCR-Treg engineering, FoxP3 stability, antigen-specific targeting, and expansion/manufacturing are the open whitespace.

CAR-Treg innovations; TCR-Treg innovations; antigen-specificity/targeting innovations; and induced-Treg (conversion) innovations represent core Treg-therapy patent domains — and TARGETING Treg suppression to the right tissue/antigen (so you suppress locally, not the whole immune system) is the central engineering goal. CAR-TREG PATENTS: engineering Tregs with a CHIMERIC ANTIGEN RECEPTOR (CAR) so they home to and suppress at a specific tissue/antigen (e.g., a transplanted organ, an autoimmune target) — providing LOCALIZED, antigen-directed tolerance (vs broad immunosuppression); CAR design tuned FOR Tregs (signaling that activates suppression, not killing — different from CAR-T) is core, high-value IP (Sonoma/Quell). TCR-TREG PATENTS: making Tregs antigen-specific via an engineered T-CELL RECEPTOR (TCR) recognizing a disease antigen (Abata's approach, e.g., a myelin antigen in MS) — TCR-Tregs target the natural disease antigen; TCR-Treg engineering is distinct, valuable IP. ANTIGEN-SPECIFICITY / TARGETING PATENTS: directing Treg suppression to the DISEASE site/antigen (the key to a safe, effective Treg therapy — local tolerance without global immunosuppression), and selecting the right target antigens; antigen-specific targeting is high-value. INDUCED-TREG (CONVERSION) PATENTS: since natural Tregs are RARE, CONVERTING abundant conventional T cells INTO functional, stable Tregs (induced Tregs / iTregs — GentiBio) by engineering FoxP3 expression and Treg programming; induced-Treg generation is a key, scalable approach and high-value IP. CAR-Treg/TCR-Treg engineering (antigen-targeted suppression) and induced-Treg generation are the highest-value engineering IP because targeting suppression to the disease and making enough stable Tregs are exactly what distinguish a precise Treg therapy from broad immunosuppression.

Treg-stability (FoxP3) innovations; expansion innovations; potency and persistence innovations; and manufacturing and safety innovations represent additional Treg-therapy patent domains — and keeping Tregs STABLE (suppressive), expanding the rare cells, and manufacturing them are the practical make-or-break challenges. TREG-STABILITY (FoxP3) PATENTS: a CENTRAL challenge — Tregs can LOSE their suppressive phenotype and even CONVERT into inflammatory (effector) T cells under inflammation, which would be dangerous (turning a brake into an accelerator); STABILIZING the Treg identity — locking FoxP3 (the master Treg transcription factor) expression, epigenetic stabilization, and resisting conversion — is critical, high-value IP (stability is what makes Treg therapy safe and durable). EXPANSION PATENTS: natural Tregs are RARE (a small fraction of T cells), so isolating and EXPANDING them (polyclonal or antigen-specific) to therapeutic numbers while preserving stability/potency — expansion protocols, purity, and maintaining the Treg phenotype during expansion; expansion/manufacturing of stable Tregs is high-value. POTENCY / PERSISTENCE PATENTS: maximizing suppressive POTENCY, in vivo PERSISTENCE, and durable tolerance (ideally 'infectious tolerance' that spreads), plus engineered cytokine support (e.g., IL-2 sensitivity). MANUFACTURING / SAFETY PATENTS: autologous vs allogeneic Treg manufacturing, consistency, safety switches/controls (to shut off if needed), and avoiding over-immunosuppression/infection risk. FoxP3/identity stabilization (the safety linchpin), stable Treg expansion/manufacturing, and durable potency/persistence are the highest-value practical IP because Treg stability, sufficient numbers, and durable safe suppression determine whether Treg therapy works without becoming dangerous.

Treg therapy startup IP strategy must navigate Sonoma/Quell/Abata/GentiBio portfolios and broad CAR/cell-therapy and Treg-biology prior art (CARs, FoxP3, and Treg immunology have substantial IP — including foundational CAR patents that also read on CAR-Tregs), the STABILITY (FoxP3) and antigen-specificity challenges, the expansion/manufacturing and safety realities, the autoimmune/transplant clinical-validation needs, the CAR-Treg-vs-TCR-Treg-vs-iTreg approach choice, and a landscape where CAR/TCR-Tregs, stability, expansion, and antigen-specificity are the durable assets; understand that CAR constructs and Treg biology are well-trodden, so the durable IP is in Treg-OPTIMIZED CARs/TCRs, FoxP3/identity stabilization, induced-Treg generation, antigen-specific targeting, and stable expansion — with CAR/Cas FTO mattering, and that stability/safety, antigen-specificity, and manufacturing matter as much as patents; identify whitespace in Treg stability, antigen-specific CAR/TCR-Tregs, and iTregs. Treg-THERAPY STARTUP IP STRATEGY: CARs AND Treg BIOLOGY ARE WELL-TRODDEN — Treg-OPTIMIZED CARs/TCRs, FoxP3 STABILITY, iTregs, AND ANTIGEN-SPECIFICITY ARE THE IP: foundational CAR/cell-therapy IP exists, so patent Treg-SPECIFIC CAR/TCR designs, stability methods, iTreg generation, and antigen-specific targeting — and clear FTO on CAR constructs (CAR-T patents can read on CAR-Tregs); FoxP3/IDENTITY STABILITY IS THE SAFETY LINCHPIN AND HIGHEST-VALUE IP: Tregs that lose suppression or convert to inflammatory cells are dangerous — locking FoxP3/Treg identity (epigenetic/engineered stability) is the most critical, defensible IP; ANTIGEN-SPECIFIC TARGETING (CAR/TCR-Treg) ENABLES LOCAL TOLERANCE: directing suppression to the disease tissue/antigen (vs broad immunosuppression) is the key value proposition — Treg-optimized CAR/TCR IP is high-value; INDUCED Tregs (iTregs) SOLVE THE RARITY/SCALE PROBLEM: converting abundant conventional T cells into stable Tregs (GentiBio) is a scalable approach and valuable IP; CAR DESIGN FOR Tregs DIFFERS FROM CAR-T: the CAR must activate SUPPRESSION (not killing) — Treg-tuned signaling is distinct, patentable; STABLE EXPANSION/MANUFACTURING IS A REAL CHALLENGE: expanding rare Tregs while keeping them stable/potent is high-value process IP; SAFETY/CONTROLLABILITY MATTERS (OVER-SUPPRESSION RISK): safety switches and avoiding infection/over-immunosuppression are important; APPROACH CHOICE (CAR-Treg vs TCR-Treg vs iTreg) SHAPES STRATEGY: each has different IP/FTO and clinical fit; WHEN TO PATENT: NOVEL CAR/TCR/STABILITY/EXPANSION WITH MEASURED OUTCOMES: file once a construct/method shows measured results (suppressive potency + Treg STABILITY (FoxP3 retention/conversion resistance) + antigen-specificity + expansion yield/purity + persistence + safety) vs. polyclonal-Treg/drug-immunosuppression baselines — measured stability, suppressive potency, and antigen-specificity are the critical Treg-therapy IP metrics; KEY FTO CHECKLIST: Sonoma/Quell CAR-Treg; Abata TCR-Treg; GentiBio iTreg; foundational CAR (CAR-T patents read on CAR-Tregs — FTO); Treg-optimized CAR signaling (suppression not killing); engineered TCR antigen-specific Treg; antigen-specific tissue targeting; FoxP3 master-regulator/epigenetic identity stabilization/conversion resistance; induced-Treg conversion from conventional T cells; Treg isolation/expansion/purity; IL-2 sensitivity/cytokine support/persistence; autologous/allogeneic manufacturing + safety switch; autoimmune/transplant/inflammation application; Treg immunology prior art.